Phil Morton

Chief Technology Officer • Albumedix

Dr. Philip Morton has a strong technology background with over 25 years’ experience in the biopharmaceutical industry within process and product development as well as product application research. He was trained as a biochemical engineer and has biopharmaceutical experience in both R&D and manufacturing environments in Albumedix under its former owners of Delta Biotechnology, Aventis and Novozymes. With his experience Phil brings a strong technological leadership to Albumedix.

Also Speaking

Jenny Holt

Senior Vice President, Programme and Portfolio Management • Ray Therapeutics

Olivier Negre

Chief Scientific Officer • Smart-Immune

Robert Hughes

Vice President & General Manager • Miltenyi Biotec

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.